Biblio

Found 12 results
[ Author(Asc)] Keyword Title Type Year
Filters: First Letter Of Last Name is E  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
E
G. Emons, Gorchev, G., Sehouli, J., Wimberger, P., Stähle, A., Hanker, L., Hilpert, F., Sindermann, H., Grundker, C., and Harter, P., Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the AGO-study group (AGO G, Gynecol Oncol, vol. 133, pp. 427-32, 2014.
G. Emile, Chauvenet, L., Tigaud, J. M., Chidiac, J., E. Lauraine, P., and Alexandre, J., A clinical experience of single agent bevacizumab in relapsing ovarian cancer, Gynecol Oncol, vol. 129, pp. 459-62, 2013.
C. Elie, Geay, J. - F., Morcos, M., Le Tourneau, A., Girre, V., Broet, P., Marmey, B., Chauvenet, L., Audouin, J., Pujade-Lauraine, E., Camilleri-Broet, S., and Group, G. I. N. E. C. O., Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group), Br J Cancer, vol. 91, pp. 470-5, 2004.
E. Eisenhauer, Bacon, M., W, W., C, M. D., R, C., N, O., and Zee, B., Long term survivors from a European-Canadian Trial of paclitaxel in platinum-pretreated ovarian cancer. , Eur J Can , vol. 33, no. 8, 1997.
E. Eisenhauer, Vermorken, J. B., and van Glabbeke, M., Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]., Ann Oncol, vol. 8, no. 10, pp. 963-8, 1997.
E. Eisenhauer and Vermorken, J. B., New drugs in gynecologic oncology., Curr Opin Oncol, vol. 8, no. 5, pp. 408-14, 1996.
E. Eisenhauer, Bacon, M., Atri, M., M, L., R, N., P, P., E, S., A, F., and N, O., Radiologic review of response in ovarian cancer: Is it useful? Results from a joint European-Canadian trial. , Proc Am Soc Clin Oncol , vol. 13, 1994.
E. Eisenhauer, Huinink, W. W. ten Bok, Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E. L., Kerr, I., Vermorken, J. B., Buser, K., and Colombo, N., European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion, J Clin Oncol, vol. 12, pp. 2654-66, 1994.
E. Eisenhauer, Addressing unanswered questions in ovarian cancer trial methodology: follow-up of the 2004 Baden-Baden Gynecologic Cancer Intergroup meeting., Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 74-5, 2008.
E. Eisenhauer, Huinink, W. W. ten Bok, Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E. L., Kerr, I., Vermorken, J. B., Buser, K., and Colombo, N., European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion., J Clin Oncol, vol. 12, no. 12, pp. 2654-66, 1994.
P. J. Eifel, Winter, K., Morris, M., Levenback, C., Grigsby, P. W., Cooper, J., Rotman, M., Gershenson, D., and Mutch, D. G., Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01, J Clin Oncol, vol. 22, pp. 872-80, 2004.
H. Earl, ICON3 and chemotherapy for ovarian cancer, Lancet, vol. 360, p. 2087; author reply 2088, 2002.